New Haven biotech Alexion Pharmaceuticals Inc. will partner with a startup in the Netherlands on a new drug to treat degenerative brain disorders. Alexion on Monday announced a deal with ...

“ Our collaboration with Dicerna to discover and develop GalXC RNAi therapies, which have the potential to inhibit uncontrolled activation of the complement system in new ways, represents an exciting ...

Some of the greatest advancements in modern medicine started with a scientist taking a risk to boldly pursue new areas of research. For scientists at Alexion — a leading biotech company dedicated to ...

Alexion Pharmaceuticals (ALXN) said Wednesday that it will acquire Achillion Pharmaceuticals to expand its pipeline of experimental drugs targeting rare diseases of the immune system. The all-cash ...

Most people are familiar with the immune system and its role in protecting against diseases and infection. But what about the complement system? The complement system is a foundational part of the ...

“Our collaboration with Dicerna to discover and develop GalXC RNAi therapies, which have the potential to inhibit uncontrolled activation of the complement system in new ways, represents an exciting ...